Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2585

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2585
---
, it is difficult to predict
whether WPDS will enable us to successfully identify or develop product candidates. It is also difficult to accurately predict the developmental
challenges we may incur for our product candidates as they proceed through product discovery or identification, preclinical studies and
clinical trials. It is difficult for us to predict the time and cost of the development of product candidates identified by WPDS, and
we cannot predict whether the application of our technology, or any similar or competitive technologies, will result in the identification,
development, and regulatory approval of any products. There can be no assurance that any development problems we experience in the future
related to our technology or any of our research programs will not cause significant delays or unanticipated costs, or that such development
problems can be solved at all. Any of these factors may prevent us from completing our preclinical studies and clinical trials that we
may initiate or commercializing any product candidates we may develop on a timely or profitable basis, if at all.

Due
to our business model, we must make decisions on the allocation of resources to certain programs and product candidates; these decisions
may prove to be wrong and may adversely affect our business.

We
may forego or delay pursuit of opportunities with respect to additional research programs or product candidates or for indications other
than those we are currently targeting. To the extent we allocate resources to any particular product candidate, our ability to pursue
development of another product candidate may be hindered. Some of these opportunities may later prove to have greater commercial potential
or a greater likelihood of success. Therefore, our resource allocation decisions may cause us to fail to capitalize on viable commercial
products or profitable market opportunities, or expend resources on product candidates that are not viable.

There
can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop
suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and
prospects. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to
be unsuccessful.

We
may not be successful in our efforts to identify or discover additional product candidates in the future.

Although
our business model relies in part on a plan to harness breakthrough inventions at research universities and medical centers and develop
them into therapeutics that can address unmet medical needs, there can be no assurance that we will ever be able to identify additional
candidate opportunities at these institutions or others. Even if we were able to identify such opportunities,